Clinical trials: Psoriatic Arthritis (PsA)
Rhumatoid Arthisis, Spondyloarthritis (SA)
Efficacy of a Self-Management Smartphone App to Improve Safety Skills in Patients With Inflammatory Arthritis
Rheumatoid arthritis (RA) and spondyloarthritis (SpA), including psoriatic arthritis (PsA), are chronic painful diseases that impair quality of life.
- Conditions
- Rhumatoid Arthisis, Spondyloarthritis (SA), Psoriatic Arthritis (PsA)
- Trial name
- RHUMATOSMART (NCT07460739)
- Testing
- SFR application
- Where
- France
- Volunteers
- 144 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Psoriatic Arthritis
A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
This is a study to demonstrate the clinical efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared with placebo in the treatment of subjects with active Psoriatic Arthritis (PsA).
- Trial name
- BE OPTIMAL (NCT03895203)
- Testing
- Bimekizumab, Adalimumab
- Where
- 136 sites in United States, Australia and 12 more
- Volunteers
- 852 people
- Sponsor
- UCB Biopharma SRL
Rheumatic Diseases, Inflammatory Arthritis
Personalized Outreach for Equitable Treatment in Rheumatology
The primary goal of this study is to determine whether providing patient honoraria and/or outreach services can improve the attendance rate of appointments at an inner city rheumatology clinic in Vancouver, British Columbia.
- Conditions
- Rheumatic Diseases, Inflammatory Arthritis, Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA)
- Trial name
- POET-Rheum (NCT07022756)
- Testing
- Honoraria, Outreach
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University of British Columbia
Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA)
REDO-JAK: Dose Reduction of Janus Kinase Inhibitors in Patients With Inflammatory Rheumatic Diseases
The goal of this clinical trial is to assess the effectiveness of a disease activity guided dose reduction strategy of Janus kinase inhibitor (JAKi) compared to disease activity guided JAKi continuation in patients with…
- Conditions
- Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Axial Spondyloarthritis (AxSpA)
- Trial name
- REDO-JAK (NCT07160231)
- Testing
- JAKi dose reduction strategy, JAKi disease activity guided continuation of same dose strategy
- Where
- 7 sites in Netherlands
- Volunteers
- 200 people
- Sponsor
- Sint Maartenskliniek